Phase II data deliver conditional EU approval for Roche cancer drug

Swiss pharmaceutical giant Roche (ROG: SIX) has been granted conditional approval from the European Medicines Agency (EMA) for its lung cancer therapy Alecensa (alectinib).

Under the provisions of the conditional approval, Roche will provide additional data on first-line Alecensa from an ongoing Phase III study. These results are expected within months.

The drug has been granted marketing authorization as a monotherapy for the treatment of certain adult patients with non-small cell lung cancer (NSCLC). This very serious condition is the leading cause of cancer-related deaths in Europe and across the world.